Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Can anyone tell me what price it would be once it relists?
.....I sold out several months ago.
The obvious really in it will need more cash as near every other company does. Far more insight looking at the %s the bod have taken.... This will get mass ii following and buying soon enough imo.
The birken sellers are getting... initial eur 1 million settled on signature of birken spa another eur 150k on completion milestone payments upto eur50 million, of which eur10 million is payable on admission royalties of 6-9% of episalvan sales for 10 years from first commercial sale. and shares in amryt totalling 30% of the fully diluted issued share capital ........... After paying out eur11.1million - the old cash balance from fastnet equity is about gone. Then.. pay $100k in cash for somtherapeutics less liabilities if over $150k pay $4.15m in shares for sompharmaceuticals. This will leave the EUR10 million from the placing to fund the eb trials. It won't be long before the additional funding is sought, if not already being looked at.
Total and utter no brainer for me buying in at these levels. Directors have snapped up 30% of Amryt Pharma PLC. thats a huge sign of confidence.
3.50p paid for 50,000
Broker just emailed me to advise is Investor Meeting on Wednesday 6th April at Double Tree by Hilton (formerly the Burlington Hotel),Dublin at 5 p.m. The presentation will be 45 mins long and speakers are Joe Wiley CEO & Rory Nealon CFO/COO of Amryt,Ray Stafford will also attend.
Joseph Wiley, chief executive elect of Amryt Pharmaceuticals, said it was a “nice endorsement” of the company’s strategy to have Harry Stratford on board as chairman. Amryt intends to focus on acquiring, in-licensing and then developing drugs for hard to treat, so-called orphan diseases. Stratford pioneered this approach as founder of Shire, the world’s largest speciality pharma company. “Having Harry on board is fantastic,” Wiley told Proactive. “It is a nice endorsement of what we want to do, given he founded what is now the largest ‘orphans’ company in the world.” Key to the short- and medium-term prospects of the firm is a skin treatment called Episalvan, developed by German specialist Birken - one of two acquisitions Amryt has made. The product is already out on the market and has been signed off for use in adults in a type of gash or ulcer called a partial thickness wound. However, the plan is to carry out a phase-III clinical trial to assess its potential to accelerate the healing process in epidermolysis bullosa (EB). This is a rare and distressing genetic disorder affecting young children that makes the skin very fragile. “It is a pretty horrific disease,” said Wiley. “In the severe forms the parents change the wound dressings every three to four days.” There is a competing treatment currently undergoing phase III trials called Zorblisa. It was discovered by Scioderm, which was then acquired by Amicus Therapeutics for up to US$847mln on the strength of phase IIb results. Wiley is unfazed by having a rival in this space. He sees Zorblisa as more of a pathfinder than competition and said: “The good part of Amicus being ahead of us is they have shown us the regulatory path to approval. We will follow similar protocol.” Also, he hopes Episalvan will have a major advantage over Zorblisa in that it can be applied once every three to four days rather than every 24 hours. The early data from a phase IIa study on EB and phase III trials in other indications for the skin treatment in adults are encouraging. Wiley said the phase III investigation ought to get underway late this year or early next, which means Amryt will have the results some time in 2018. Episalvan has been awarded orphan drug designation (ODD) in the US and the EU for EB, and the market for this indication alone is estimated to be US$1.5bn. Orphan designation often means the product can be fast-tracked – usually at a fraction of the cost of developing medication destined for the mass market. And, as they are niche areas where there are no current treatments, firms are often allowed to charge more for a breakthrough new product. Around 19% of all prescriptions are for these rare ailments, and the market globally is estimated to be worth US$176bn.
from the rns today.. The Enlarged Group will utilise the net proceeds of the placing to focus on the opportunity presented within the EB market as described below. Subject to securing additional capital, which may come from alternative sources such as licencing deals or venture debt, the Enlarged Group would have the ability to exploit its other assets, Episalvan in respect of PTWs which has been approved for use in Europe and its preclinical assets focused on Acromegaly and Cushing's disease, Meaning, after the placing and a bit of time, they will be looking for further funding.
Iirc they had about £9m in cash at suspension, they are taking over amryt in a £29.6m reverse takeover and raising £10m in a placing, which when added up comes to about the £50m cap.
thanks Sea7
Nope, they will consolidate 8 for 1, issue the consideration shares for the purchase of amryt, carry out the placing at 24p, to raise £10m then, in addition to the warrants/options there will be, on the 19th April, 236,687,257 shares in issue, fully diluted. At 24p this is a cap of £56.8m, without options/warrants it is 208,339,632 x 24p which is a mcap of £50m as indicated in the rns's today. The stock will open at 24p and go from there.
Good point
so am I right in thinking that there will be consolidation of 8 to 1 that currently means we would open at 25.6p however there will immediately be a placing at 24p?
1 of many delayed trades I reckon
There is every chance it will run higher on the 19th april, however, it may slowly decline below that as the days roll on. Wouldn't be the first aim stock I have seen do that.
And what if the price opens higher than 24p? Your forgetting free little free float so the chances of trading well above 24p is more likely
There will be an 8 for 1 consolidation, with the placing price at 24p. Buying over 3p today means a loss to start with, after the consolidation. I will be waiting for the price to get down to three pence, or I will wait until after the whole process is completed and look to buy in, if and when the price goes below the 24p price, which is possible. Buy £2k today at 3.4p you get 58,823 shares - consolidate 8 for 1, you are left with 7,352 shares. Say the stock starts at 24p placing price on 19th april, your stock would be worth 7,352 x 24p = £1,764.28. Buy £2k at 3p, you get 66,666 shares, consolidate 8 for 1 you get 8,333 shares x 24p = £1999.92. No point buying at over 3p, prior to consolidation.
Think now trading resumed on most platforms...good luck all as loooing good from what I have looked into
not many shares in free float.Long way to go.
Thanks people, just been on the phone with selftrade. Cant do anything about it as not loaded up on their system yet. I have to send a secure message to ask them to do it. Not very good service good look everyone
i paid 3.375 per share
I just got some on td waterhouse working fine here
Harry Stratford has over 40 years' experience in the pharmaceutical industry and has built two successful publicly listed pharmaceutical companies. Harry founded Shire Plc in 1986 and was CEO for almost a decade. The Company has grown from humble beginnings to be one of Europe's largest specialty pharmaceutical companies with a market cap of around $40 billion and its stock is a constituent of the FTSE100 index. Harry then went on to be founder, CEO and Executive Chairman of Prostrakan Plc, another International specialty pharmaceutical company, which was subsequently acquired by Kyowa Hakko Kirin of Japan in 2011. Harry holds a BSc. in Chemistry from the University of London and was awarded an OBE in the 2007 New Year's Honours list for his contribution to the Scottish Life Sciences Industry.
Just back on halifax so shoild be able to buy again soon...still as fast epic on there